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Abstract 
Background 
This report studies the early and medium term clinical and echocardiographic outcomes of 
the Alfieri edge-to-edge mitral valve repair, as adjunctive therapy, to prevent and treat 
systolic anterior motion at time of septal myectomy for left ventricular outflow tract 
obstruction in hypertrophic cardiomyopathy. 
Methods 
From 2009-2015, 11 initial and consecutive patients had a trans-atrial Alfieri repair, to 
prevent (n=7) or treat (n=4) systolic anterior motion at the time of septal myectomy. 
Results 
No patients were lost to follow-up. There were no perioperative or late deaths. Pre-bypass, 
the mean left ventricular outflow tract gradient, measured directly by simultaneous needle 
insertion, was 40.7+/-19.9mmHg at rest and 115.8+/-30.4mmHg on provocation with 
Isoproterenol, which reduced after septal myectomy and Alfieri repair and discontinuation of 
bypass, to a mean gradient of 8.3+/-9.8mmHg at rest and 25.8+/-9.2mmHg on provocation. 
One patient who required mitral valve replacement on day 4, was hospitalised at 2.7 years 
with heart failure requiring diuresis and remains well at 6 years. One patient developed 
perioperative atrial fibrillation. There were no other early or late complications.  
At a median follow-up of 6.6 years (IQR 1.2-7.4), clinical and echocardiographic data 
demonstrated maintained improvement in mean NYHA class from 2.6+/-0.9 preoperatively to 
1.7+/-0.4 and reduction in mean grade of mitral regurgitation from 2.7+/-0.8 preoperatively to 
0.7+/-0.6. 
Conclusions 
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The Alfieri repair, as adjunctive therapy, for the prevention or treatment of systolic anterior 
motion at time of septal myectomy demonstrates satisfactory early and medium term clinical 
and echocardiographic outcomes supporting the ongoing utility of this approach. 
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Introduction 
Septal myectomy (SM) is indicated in selected patients for the management of drug 
refractory symptomatic left ventricular outflow tract obstruction (LVOTO) in hypertrophic 
cardiomyopathy (HCM).1 The mechanism of LVOTO involves both the left ventricular outflow 
tract (LVOT) and the mitral valve apparatus at various levels, especially when the anterior 
mitral valve leaflet is elongated.2-4 Septal myectomy alone is adequate in the surgical 
management of LVOTO in the vast majority of patients with HCM.5,6 Concomitant mitral 
valve repair at the time of SM can be used to prevent or treat post SM systolic anterior 
motion (SAM) related mitral regurgitation (MR) or residual unacceptably high LVOT 
gradients.7-10 This approach to SAM which is required in a small minority of such patients 
can avoid mitral valve replacement (MVR) and its associated increased mortality and 
morbidity.5,6,11,12 Previous studies using the “edge to edge” mitral repair technique described 
by Alfieri et al, have shown good outcomes in the correction of MR from diverse aetiologies 
such as degenerative, ischemic and functional.13-17 This study investigates early and 
medium-term outcomes in a group of 11 consecutive patients undergoing an Alfieri mitral 
valve repair (AR) at the time of SM for the prevention and treatment of SAM. 
 
 
Materials and Methods 
A retrospective analysis was carried out in a cohort of patients with HCM who had a SM and 
AR for management of LVOTO by a single surgeon (CMcG). A diagnosis of HCM was 
defined as per international guidelines.1 No patient had undergone previous management of 
LVOTO with surgery, alcohol septal ablation or dual chamber pacing. Preoperative clinical 
assessment was undertaken by a team of specialist HCM cardiologists in a national referral 
centre. 
 
 5 
Patients 
The study consisted of 11 initial and consecutive patients, 7 males, 4 females, having an AR 
as part of SM surgery for LVOTO with HCM from April 2009 to August 2015 out of a total of 
123 SM patients operated on in that period. The mean age of the AR patients was 47.5+/-
13.9 years. All patients preoperatively had drug refractory symptomatic LVOTO at rest (n=8) 
or on provocation with the Valsalva manoeuvre (n=3). Surgical strategy was individualised 
preoperatively, including a multidisciplinary team review of all imaging. In particular, the 
potential use of adjunctive AR was considered and discussed in patients with reduced septal 
thickness or those with intrinsic mitral valve abnormalities. The aim of the AR was to reduce 
anterior leaflet SAM by attachment to a normal or tethered posterior leaflet. Specific 
attention was made to posterior mitral leaflet length to avoid bileaflet anterior motion post 
AR. The indications for an AR in this series included; elongated anterior mitral valve leaflets 
(n=5), leaflet prolapse (n=2), significant residual SAM related MR or residual unacceptable 
LVOT gradients on provocation after SM on the discontinuation of cardiopulmonary bypass 
(n=4). Eight patients had concomitant surgery to suture close the orifice of the left atrial 
appendage and 1 had a MAZE procedure for atrial fibrillation (AF).  
 
Assessment and Follow-up 
Echocardiograms were assessed preoperatively, and postoperatively, at regular follow-up 
intervals, including annually. Provocation using Valsalva or exercise echocardiography was 
performed if clinically indicated. No patients were lost to follow-up. Perioperative 
complications were defined as those occurring during hospitalisation or within 30 days of 
surgery. Late complications were defined as those occurring after this period. 
 
Surgical Assessment and Technique 
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Perioperative transoesophageal echocardiography (TOE) was performed. After median 
sternotomy and before cardiopulmonary bypass, direct simultaneous pressure 
measurements were performed with needles in the aorta and left ventricle. Provocation was 
measured following a bolus of Isoproterenol (5mcg) intravenously and repeated if an 
increase in heart rate and/or reduction in blood pressure was not achieved. The technique of 
SM is based on the Danielson modification of the classic Morrow Myectomy.18 Following this 
if planned preoperatively, the AR was done trans left atrially in a standard fashion by 
approximating the central free edges of the A2 and P2 scallops of the mitral valve using a 
pledgeted 4-0 Goretex suture.15,16 After cardiopulmonary bypass TOE was done to 
assess the LVOT and mitral valve function. In addition, direct simultaneous pressure 
measurements were repeated with and without provocation as done pre-bypass. Indications 
to resume bypass and perform an AR at this point were a significant residual gradient, 
and/or persistent SAM related MR. Mitral annuloplasty was avoided in all patients. 
 
Statistical Analysis 
Data was analysed using SPSS Version 24 (IBM, Chicago). Variables collected included 
baseline demographics, New York Heat Association (NYHA) clinical classification, 
echocardiographic parameters (MR grade, SAM, ejection fraction, LVOT gradients) and 
postoperative outcomes. Variables were expressed as a mean with standard deviation or 
median with interquartile range as appropriate. Comparisons were made using paired t-
tests. A p-value of <0.05 was considered significant. 
 
 
Results 
 7 
There were no perioperative or late deaths. The median follow-up duration was 6.6 years 
(IQR 1.2-7.4). No patient was lost to follow-up. Septal tissue excised at myectomy weighed a 
mean of 4.3+/-3.6 grams. Intraoperatively, pre-bypass, the mean resting LVOT gradient was 
40.7+/- 19.9mmHg and on provocation with Isoproterenol was 115.8+/-30.4mmHg. Following 
surgical resection and AR, the mean resting LVOT gradient reduced to 8.3+/-9.8mmHg and 
on provocation was 25.8+/-9.2mmHg. The mean hospital stay was 10+/-3 days. One patient 
required a MVR on day 4 postoperatively due to severe MR. This was a 46-year-old man 
who preoperatively had a right atrial pressure of 21mmHg, pulmonary pressures >60mmHg, 
severe concentric left ventricular hypertrophy, complete SAM and severe MR with a dilated 
left atrium. He firstly underwent an extended SM (10 grams of tissue removed), with a MAZE 
procedure and planned AR. Intraoperatively there was resolution of obstruction with no 
significant gradient on provocation. Postoperatively, over the following days, he required 
increasing inotropic support to maintain adequate circulation. Echocardiography revealed 
severe MR. A MVR, inserting a 33mm St Jude mechanical prosthesis, was performed on 
day 4. The papillary muscles were found to be thickened and fibrosed. The patient was 
discharged home well on day 12. He had 1 hospitalisation at 2.7 years for management of 
heart failure with diuresis, and continues to be symptomatically well on latest follow-up at 6 
years. Another patient had a brief episode of AF perioperatively, successfully chemically 
cardioverted. One patient, a 73-year-old man, with preoperative first degree atrioventricular 
block and left bundle branch block had a planned prophylactic dual chamber pacemaker 
inserted postoperatively. 
 
At 1 year follow-up, the mean NYHA class had improved from 2.6+/-0.9 preoperatively to 
1.6+/-0.7 and on most recent follow-up (median 6.6 years) was 1.7+/-0.4. Nine of the 11 
patients showed an improvement in NYHA functional class to NYHA Class I/II, while 2 
patients remained in the same functional class (NYHA III). One of the 2 patients who 
remained in the same functional class, was diagnosed with lung and liver metastases of 
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unknown primary. He subsequently underwent chemotherapy with an ongoing good 
response. The other patient was a 64-year-old woman with multiple comorbidities limiting 
her functional capacity, including ongoing smoking, chronic obstructive pulmonary disease 
and severe osteoarthritis, subsequently having a knee replacement and who remains limited 
(NYHA III) at 7 years. There were no other late complications in the series. 
 
Echocardiographically (Table 1), the mean interventricular septal wall thickness (IVS) 
reduced from 17.5+/-3.0mm preoperatively to 15.5+/-3.8mm at 1 year and 16.1+/-3.5mm at 
most recent follow-up (median 6.6 years). Changes in left atrial diameter (LAD) and left 
ventricular end diastolic dimensions (LVEDD) were not significant at 1 year or on most 
recent follow-up compared to preoperatively. The mean grade of MR improved from 2.7+/-
0.8 preoperatively to 1.0+/-0.9 at 1 year, and 0.7+/-0.6 at most recent follow-up. The mean 
resting left ventricular outflow tract gradient reduced from 59.8+/-28.2mmHg preoperatively 
to 20.7+/-16.6mmHg at 1 year and 16.2+/-15.7 at most recent follow-up. All 11 patients had 
documented SAM on the preoperative echocardiogram. No patient had SAM on the 
postoperative echocardiogram at 1 year.  
 
 
Discussion 
Isolated septal myectomy is the only surgical procedure required in the vast majority of 
patients with LVOTO in HCM.4,5 The incidence of SM with concomitant mitral valve repair in 
this study (11 of 123 overall SM cases) is consistent with the 7% reported recently in the 
largest study to date of over 2000 patients from the Mayo Clinic, also discussed 
subsequently in an editorial.5,6 The type of mitral repair was not described in the Mayo study. 
A number of surgical techniques have been utilised on the mitral valve to eliminate SAM in 
the context of SM.7-10 The optimal surgical strategy remains uncertain.5 Systolic anterior 
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motion of the anterior mitral valve leaflet after SM can result in residual unacceptable levels 
of LVOTO and/or MR post procedure. As in the Mayo study, if further septal resection was 
judged inappropriate due to limited septal thickness, mitral valve repair was our preferred 
approach to reduce this residual LVOTO and/or MR whenever possible, and avoid the 
limitations of valve replacement.5,11,12 Alfieri and colleagues introduced a technique in 1995 
describing an edge to edge repair to approximate the central mitral valve edges creating a 
double orifice to alleviate MR.15 This technique has been studied in larger cohorts 
undergoing surgery for primary MR with good long term outcomes.13-17 Previous studies with 
long term follow up from AR showed rates of freedom from reoperation of 90% at 5 years 
and survival rates of 94% at 5 years.16  
 
There are few papers describing AR in the context of LVOTO in HCM. These report short 
term results only with limited echocardiographic follow-up. In a subgroup of 14 patients who 
underwent AR without annuloplasty after SM at the Cleveland Clinic, two patients required 
subsequent MVR.17 This study, using the trans aortic AR technique, reported an encouraging 
early experience of AR in HCM, but had limited follow up data compared to the longer 
clinical and echocardiographic follow-up in this current study. A further study by Shah et al, 
focused on perioperative complications following trans aortic AR in 24 patients with LVOTO 
in HCM with short, limited follow-up data with 1 early mortality from a ventricular septal 
defect (VSD).19 Recently Obadia et al, report outcomes in 22 patients with trans aortic AR 
after SM with shorter follow-up and early echocardiographic data only.20 The remainder of 
the literature consists of case reports.  
 
Our data reports, for the first time, medium term clinical and echocardiographic outcomes of 
AR after SM in HCM with a median follow-up of 6.6 years. Interventricular septal wall 
thickness was reduced from 17.5+/-3.0 preoperatively to a mean of 15.5+/-3.8 
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postoperatively at 1 year. An AR was performed rather than further resection either because 
residual thickness was such that a further resection was regarded as high risk for VSD, or 
the patient had a known mitral leaflet abnormality. This partly reflects the varying clinical 
phenotype of patients in HCM, with less hypertrophy seen in the sub group of patients 
treated in this study compared to Obadia et al, who report a mean septal wall thickness 
preoperatively of 25mm.  
 
As in the Cleveland series, a concomitant mitral annuloplasty, almost uniformly done at the 
time of general mitral repair including the AR, was avoided in this series of HCM patients, to 
avoid any propensity to worsening SAM.17 The use or lack of use of mitral annuloplasty in 
the subset of patients with mitral valve repair after septal myectomy was not reported in the 
large Mayo series or by the studies from Shah et al and Obadia et al.5, 19, 20 The avoidance of 
annuloplasty has not compromised the results of AR in the current series at medium term 
follow-up.  
 
The relative merits of trans atrial AR, done in this study, versus trans aortic AR remain to be 
clarified by larger series with longer follow up. In the context of LVOTO and HCM there is 
limited experience with the trans aortic approach.17,19, 20 Literature on the AR for other 
aetiologies of MR has principally used the trans atrial approach which was utilised in this 
cohort.  
 
The favourable early and medium term clinical and echocardiographic outcomes in the 
current study demonstrate the benefit of trans atrial AR for the prevention or treatment of 
SAM at the time of SM in the management of LVOTO. In the current study, functional 
outcomes, assessed using NYHA classification, were comparable to a recent meta-analysis 
looking at long term follow-up in general septal reduction therapy.21 There was no early or 
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late mortality, few early or late complications and good symptomatic and echocardiographic 
outcomes. 
 
Limitations 
This paper represents a small, single centre, single surgeon, retrospective experience. The 
sample size is small, so that conclusions must be guarded, but appears to be the largest 
study to date looking at more medium term as well as early, clinical and echocardiographic 
outcomes of the AR for the treatment of SAM post SM in HCM. The absence of measured, 
documented mitral valve morphometry is a weakness in this, as in most relevant studies. 
 
 
Conclusions 
This study of good early and medium term, clinical and echocardiographic outcomes in 11 
consecutive patients using trans atrial AR without annuloplasty, as adjunctive therapy, for 
the prevention or treatment of SAM at the time of SM in the management of LVOTO in HCM 
supports further study of the ongoing utility of this approach to address a sometimes difficult 
surgical challenge. 
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Table 1 
 
Preoperatively 1 Year (n=11) P Value (Comparison at 
1 year and 
preoperatively 
Most recent 
follow-up 
(n=11) 
P Value (Comparison 
on most recent follow-
up and preoperatively) 
Interventricular 
Septal Thickness 
(mm) 
17.5+/-3.0  15.5+/-3.8  <0.05 16.1+/-3.5 0.07 
Posterior Wall 
Thickness (mm) 
9.6+/-2.1 9.7+/-0.9 0.77 11.1+/-2.3 0.22 
Left Atrial Diameter 
(mm) 
46.6+/-8.7 47.7+/-8.1 0.89 44.3+/-8.8 0.23 
Left Ventricular End 
Diastolic Diameter 
(mm) 
45.5+/-4.9 45.4+/-5.4 0.88 43.5+/-6.5 0.41 
Ejection Fraction (%) 72.0+/-9.8 64.4+/-9.9 0.59 62.2+/-6.2 <0.05 
Resting Left 
Ventricular Outflow 
Tract Gradient 
(mmHg) 
59.8+/-28.2 20.7+/-16.6 <0.05 16.2+/-15.7 <0.05 
Mitral Regurgitation 2.7+/-0.8 1.0+/-0.9 
 
0.7+/-0.6  
Table 1: Mean echocardiographic variables with pre and post-operatively comparisons using 
paired t-tests (significance, p<0.05) 
 
 
